ERBB2 and breast carcinoma: NK-92 cells carrying CARs with CD28/CD3ζ and 4-1BB/CD3ζ signaling domains have stronger cytotoxicity than CARs with only CD3ζ in killing HER2-expressing breast carcinoma cells [107].